Concepedia

Carla M. Visseren Grul

CM

Statistics

Publications

4

Citations

109

H-Index

4

Active since

2011

Affiliations

Eli Lilly (Netherlands)(Current)

Japanese Foundation For Cancer Research

Carla M. Visseren Grul is an author at Eli Lilly (Netherlands) specializing in oncology, medicine, and lung cancer.

Publications per year

2011–2024

4

Publications

4

PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · Journal of Clinical Oncology · 2011 · 46 citations

, , +17

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · Journal of Clinical Oncology · 2019 · 34 citations

, , +9

PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

L. G. Paz-Ares, F. De Marinis, M. Dediu et al. · Journal of Clinical Oncology · 2011 · 19 citations

, , +17

SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC.

Marcelo V. Negrão, Kathryn C. Arbour, Timothy F. Burns et al. · Journal of Clinical Oncology · 2024 · 10 citations

, , +9

1–4 of 4